Integration of neoadj style='font-family:Verdana;'>u style='font-family:;' '=''> style='font-family:Verdana;'>vant chemotherapy (NCT) in early 70s resulted '/> Oncoplastic Breast Surgery after Neoadjuvant Chemotherapy Replacing Mastectomy in Locally Advanced Breast Cancer (LABC): Single Institute Experience
首页> 外文期刊>Journal of Cancer Therapy >Oncoplastic Breast Surgery after Neoadjuvant Chemotherapy Replacing Mastectomy in Locally Advanced Breast Cancer (LABC): Single Institute Experience
【24h】

Oncoplastic Breast Surgery after Neoadjuvant Chemotherapy Replacing Mastectomy in Locally Advanced Breast Cancer (LABC): Single Institute Experience

机译:Neocoplastic乳房手术在局部晚期乳腺癌中取代乳房切除术后(Labc):单一学院经验

获取原文
           

摘要

>Background: style="font-family:Verdana;"> Integration of neoadj style="font-family:Verdana;">u style="font-family:;" "=""> style="font-family:Verdana;">vant chemotherapy (NCT) in early 70s resulted that many LABC tumors become resectable but with total mastectomy especially those with partial response, oncoplastic techniques give better oncological outcome with better cosmetic results. style="font-family:Verdana;">Objective: style="font-family:Verdana;"> We evaluate the oncological safety of oncoplastic breast surgery (OS) in LABC showing partial response to NCT. style="font-family:Verdana;">Methods: style="font-family:Verdana;"> We prospectively analyzed the data of 32 out of 58 patients with LABC who showed partial response to NCT and could have > style="font-family:Verdana;">conservative surgery with advanced name="OLE_LINK38">name="OLE_LINK39"> style="font-family:Verdana;">oncopla style="font-family:Verdana;">s style="font-family:Verdana;">tic style="font-family:Verdana;"> techniques rather than total style="font-family:;" "=""> style="font-family:Verdana;"> mas> style="font-family:Verdana;">tectomy. style="font-family:Verdana;">Results: style="font-family:Verdana;"> Out of 58 patients with LABC, received neoadjuvant che style="font-family:Verdana;">motherapy, complete response was observed in 8 patients (13%), partial response reported in 32 (55.1%) cases, 12 patients (20%) had stable disease and 6 patients (10%) showed progressive disease. Data of 32 cases were studied (mean age 44.84 ± 9.10 years; range 26 style="font-family:;" "=""> style="font-family:Verdana;">- style="font-family:;" "=""> style="font-family:;" "=""> style="font-family:Verdana;">59 years). Inferior pedicle was performed in 9 cases, mini LD flap in 3 patients, 5 had name="OLE_LINK40">name="OLE_LINK41"> style="font-family:Verdana;">Grissotti technique, 6 with name="OLE_LINK42">name="OLE_LINK43">name="OLE_LINK44"> style="font-family:Verdana;">super style="font-family:Verdana;">o style="font-family:Verdana;">medial style="font-family:Verdana;"> pedicle, 4 had V mammoplasty and 3 with J mammoplasty and 2 had style="font-family:;" "=""> style="font-family:Verdana;"> vertical mammoplasty. Margins were positive in 5 cases (15.6%) with mean mar style="font-family:Verdana;">gin width 9.63 style="font-family:;" "=""> style="font-family:Verdana;">± style="font-family:;" "=""> style="font-family:Verdana;">5.72 (range 0 style="font-family:;" "=""> style="font-family:Verdana;">- style="font-family:;" "=""> style="font-family:Verdana;">22 style="font-family:;" "=""> style="font-family:Verdana;">mm), and the local recurrence was re style="font-family:;" "=""> style="font-family:Verdana;">ported style="font-family:Verdana;">in 2 cases (6.2%). Complications were reported in 3 cases (9.3%)>>>>> style="font-family:Verdana;">.>> style="font-family:;" "="">>> style="font-family:Verdana;"> The follow style="font-family:Verdana;"> up was 1.67 ± 1.03 style="font-family:;" "=""> style="font-family:Verdana;">(range style="font-family:;" "=""> style="font-family:Verdana;">0 style="font-family:;" "=""
机译:>背景: style =“font-family:verdana;”> neoadj style =“font-family:verdana;”> U <跨度样式=“font-family :;” “=”> <跨度样式=“Font-Family:Verdana;”> vant化疗(NCT)在70年代初期使得许多Labc肿瘤变得可重复,但总乳房切除术尤其是患有部分反应的术语,蜂窝类技术会产生更好的肿瘤技术更好的化妆品结果。 <跨度样式=“font-family:verdana;”>目标: style =“font-family:verdana;”>我们评估Labc中肿瘤乳房手术(OS)的肿瘤疾病显示出对NCT的部分反应。 <跨度样式=“font-family:verdana;”>方法: <跨度样式=“Font-Family:Verdana;”>我们预期分析了58名Labc患者中的32例数据,该数据显示了对NCT的部分反应,并且可以具有 > style =“font-family:verdana; “>保守手术与高级 name="ole_link38"> name="ole_link39"> style =”font-family:verdana;“> oncopla style =“font-family:verdana;”> s style =“font-family:verdana;”> tic style =“font-family:verdana;”>技术而不是总计 style =“font-family :;”“=”“> style =”font-family:verdana;“ > mas > style =“font-family:verdana;”> tectomy。 <跨度样式=“font-family:verdana;”>结果: style =“font-family:verdana;”>在58例labc患者中,收到Neoadjuvant Che 母乳,在8名患者中观察到完全反应(13%),部分反应报告32例(55.1%)案件,12例患者(20%)稳定疾病,6例患者(10%)显示出渐进性。研究了32例的数据(平均年龄为44.84±9.10年;范围26 style =“font-gryse :;”“=”> style =“字体-Family:Verdana;“> - style =”font-family :;“”=“> style =”font-family :;“”=“”> style =“font-family:verdana;”> 59岁)。下椎弓根在9例中进行,3例患者迷你LD襟翼,5例 name="ole_link40"> name =“ole_link41”> style =“font-family:verdana;”> grissotti技术,6带 name="ole_link42"> name =“ole_link43 “> name="ole_link44"> style =”font-family:verdana;“> super style =”font-family:verdana ;“> style =”font-family:verdana;“> medial style =”font-family:verdana;“>椎弓根,4有v乳房成形术和3 mammoplasty和2有 style =“font-womain :;”“=”“> style =”font-family:verdana;“>垂直乳房成形术。 MARGINS在5例(15.6%)中呈阳性(15.6%),平均MAR GIN宽度9.63 样式=“font-family:verdana;”>± style =“font-gryse :;”“=”“> 样式=“Font-Family:Verdana;”> 5.72(范围0 style =“font-romain :;”“=”> style =“font-family:verdana;” > - style =“font-family :;”“=”“> style =”font-family:verdana;“> 22 style =”字体-Family :;“”=“”> style =“font-family:verdana;”> mm),并且当地复发是重新发生的re style =“font-womain :; “”=“> style =”font-family:verdana;“> ported style =”font-family:verdana;“> 2例(6.2%)。 3例(9.3%) > > > > > style =“font-family:verdana;”>。 > > style =“font-family :“ “=”“> > > style =”font-family:verdana;“>以下 style =”font-family :Verdana;“> Up是1.67±1.03 style =”font-romain :;“”=“> style =”font-family:verdana;“>(范围< / span> style =“font-family :;”“=”“> style =”font-family:verdana;“> 0 style =”font-family: ;“”=“”

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号